guanfacine and Perceptual Disorders studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Perceptual Disorders: Cognitive disorders characterized by an impaired ability to perceive the nature of objects or concepts through use of the sense organs. These include spatial neglect syndromes, where an individual does not attend to visual, auditory, or sensory stimuli presented from one side of the body.

Research Excerpts

Excerpt	Relevance	Reference
"Thirteen right hemisphere stroke patients with leftward neglect were included in a randomised, double-blind, placebo-controlled proof-of-concept crossover study that examined the effects of a single dose of guanfacine."	9.27	Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke. ( Cohen, DL; Dalmaijer, ES; Gorgoraptis, N; Husain, M; Leff, AP; Li, KMS; Malhotra, PA; Parton, AD, 2018)
"Thirteen right hemisphere stroke patients with leftward neglect were included in a randomised, double-blind, placebo-controlled proof-of-concept crossover study that examined the effects of a single dose of guanfacine."	5.27	Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke. ( Cohen, DL; Dalmaijer, ES; Gorgoraptis, N; Husain, M; Leff, AP; Li, KMS; Malhotra, PA; Parton, AD, 2018)
"Guanfacine may prove to be a useful tool in the treatment of disorders of attention associated with neurological conditions."	1.37	Attention deficits following ADEM ameliorated by guanfacine. ( Farmer, SF; Husain, M; Malhotra, P; Singh-Curry, V, 2011)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Performance on Tests of Hemispatial Neglect and Sustained Attention

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Dalmaijer, ES	1
Li, KMS	1
Gorgoraptis, N	1
Leff, AP	1
Cohen, DL	1
Parton, AD	2
Husain, M	3
Malhotra, PA	2
Singh-Curry, V	1
Malhotra, P	1
Farmer, SF	1
Greenwood, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage[NCT00955253]	Phase 2	13 participants (Actual)	Interventional	2010-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Touchscreen Cancellation: This is a computerised scale for measuring the severity of spatial neglect as described in previous publications (Malhotra et al, Annals of Neurology 2006; Parton et al, Neuroreport 2006). Patients are asked to find and touch targets (which are embedded amongst distractors) on a touchscreen. In the variant of the task employed here, the targets are not marked when touched (Invisible Cancellation).The maximum number of targets that can be found is 64 (Therefore minimum score =0, maximum = 64), which represents normal performance." (NCT00955253)
Timeframe: 5 days

Intervention	Number of targets found (Mean)
	Touchscreen Cancellation-Guanfacine	Touchscreen Cancellation-Placebo
All Patients	31.15	26.15

Article	Year
Attention deficits following ADEM ameliorated by guanfacine. Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:6 Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Arousal; Attention; Encephalomyelitis, Acute Disseminat	2011
Noradrenergic modulation of space exploration in visual neglect. Annals of neurology, 2006, Volume: 59, Issue:1 Topics: Adrenergic alpha-Agonists; Animals; Attention; Guanfacine; Humans; Neuropsychological Tests; Norepin	2006

guanfacine and Perceptual Disorders